All Episodes
|
182
|
Tyson Frodin

Podcast 182: Pharmacy as a Strategic Asset in Health Systems w/ Dr. Tyson Frodin, AVP of Pharmacy, MultiCare

Apr 3, 2025

Episode Summary

In another installment of our Pharma Series,  we're joined by Dr. Tyson Frodin, Assistant Vice President of Pharmacy at MultiCare, to explore the evolving role of pharmacy in health care. Tyson shares insights from his diverse career path - from his early experience in telehealth on a Navajo reservation, to leading pharmacy initiatives at a top health system in the Pacific Northwest. They dive into the challenges of critical access hospitals, the importance of innovation in pharmacy, and how MultiCare is leveraging technology to improve patient care.

Episode Notes

In another installment of our Pharma Series,  we're joined by Dr. Tyson Frodin, Assistant Vice President of Pharmacy at MultiCare, to explore the evolving role of pharmacy in health care. Tyson shares insights from his diverse career path - from his early experience in telehealth on a Navajo reservation, to leading pharmacy initiatives at a top health system in the Pacific Northwest. They dive into the challenges of critical access hospitals, the importance of innovation in pharmacy, and how MultiCare is leveraging technology to improve patient care.

🎙 ABOUT DR. TYSON FRODIN

Dr. Tyson Frodin is a results-driven pharmacy executive with over 15 years of experience leading large-scale transformations in pharmacy operations, supply chain, revenue cycle, and technology. As the Assistant Vice President of Clinical Pharmacy Services, Pharmacy Supply Chain, Revenue Cycle, and Technology at MultiCare Health System, he oversees a $360 million drug spend and $1 billion in revenue, driving enterprise-wide efficiencies, cost savings, and high-quality patient care.

A proven innovator in pharmacy technology, regulatory compliance, and 340B program management, Tyson has successfully centralized supply chain operations, optimized drug utilization, and led strategic partnerships—most notably securing over$1.75 million in savings through a collaboration with Mark Cuban’s Cost Plus Drugs. His leadership extends to implementing advanced data analytics, negotiating direct manufacturer contracts, and improving financial sustainability through revenue cycle enhancements.

Tyson holds a Doctorate of Pharmacy from Idaho State University and a Master of Health Care Administration from the University of Minnesota School of Public Health. He is a Fellow of the American College of Healthcare Executives (FACHE) and a Certified Pharmacy Executive Leader (CPEL). Passionate about innovation, collaboration, and strategic leadership, he is dedicated to advancing pharmacy practice and shaping the future of healthcare.

🎙 ABOUT HEALTH CARE ROUNDS Health Care Rounds is a weekly podcast developed for health care leaders who are at the forefront of health care delivery and payment reform. Join Darwin Research Group founder and CEO John Marchica as he discusses the latest advancements in health care business news and policy developments.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD
Podcast 192: Making Value-Based Care Work at Scale w/ David Carmouche, MD
Podcast 191: Curing Nursing Burnout Through Education w/ Dr. Adele Webb
Podcast 190: The New Rules of Health System Leadership w/ John D’Angelo, MD, FACEP

Recommended Content

Browse Library
INsights
January 14, 2026

Darwin's Our Take: Lilly’s ‘triple G’ candidate exceeds analysts’ expectations

Read More
INsights
January 5, 2026

Darwin's Our Take: FDA approves Novo Nordisk’s Wegovy pill

Read More
INsights
December 22, 2025

Darwin's Our Take: Another 9 drugmakers agree to most-favored-nation pricing on certain products

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.